Intracranial hemorrhage (ICH) is one of the most devastating bleeding complications associated with anticoagulation therapy. Approximately 7000 ICHs occur annually as a result of treatment with anticoagulants. Major risk factors are advanced age, elevated blood pressure (BP), intensity of anticoagulation, and previous cerebral ischemia. Combining aspirin and anticoagulants or antiplatelet agents also increases the risk of ICH. It is well known that careful monitoring of the international normalized ratio and avoidance of potentially dangerous drug combinations may make anticoagulation less risky. A review of the literature also suggests that modest BP reduction greatly reduces the risk of ICH. A study of patients with previous stroke or transient ischemic attack who were receiving antiplatelet agents or oral anticoagulants demonstrated a 50% decrease in stroke with a reduction of 9 mm Hg in systolic BP. A decrease of 76% was noted in patients who achieved systolic BP reductions of 12 mm Hg.
Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs